TVTX

Travere Therapeutics, Inc. (TVTX) Economic Moat Analysis (2026)

Invetso Score: 2.8/10 — Weak · Last Updated: 2026-08-01

Overall Score

Profitability Returns

Gross margin remains very high at 94.4%, but operating profitability is still negative with EBIT margin at -9.7% and net margin at -7.4%.

Returns remain deeply negative, with ROIC at -6.2%, ROE at -55.8%, and ROA at -5.4%, indicating no durable earnings power yet.

Balance Sheet Financial Strength

Liquidity is solid with a current ratio of 4.0 and quick ratio of 4.0, providing near-term flexibility.

Leverage remains very high, with debt-to-equity at 25.2x and net debt to EBITDA at 323.3x, which limits financial resilience.

Pricing Power Unit Economics

Gross margin of 94.4% suggests strong product-level pricing economics, but that has not translated into positive operating margins.

Cash conversion is positive, with operating cash flow margin at 15.7% and free cash flow margin implied by FCF yield, but valuation remains extremely demanding at 10.5x sales and 111.0x free cash flow.

Competitive Positioning

The business shows some moat-like characteristics in its high gross margin and strong fixed-asset turnover, but the lack of profitability weakens evidence of a durable competitive advantage.

Heavy R&D spend at 38.4% of revenue indicates continued investment, but it also underscores that the moat is still being built rather than fully proven.

Sources

  • Company filings (10-K, 10-Q, investor presentations)
  • Financial and market data providers
  • Public news and industry information

🔒 Go Beyond This Framework

This is one of 10 institutional-grade frameworks Invetso runs on Travere Therapeutics, Inc.. Unlock the complete analysis — SWOT, Economic Moat, Porter’s Five Forces, Management, PESTLE and the Invetso Quality Score.

Create your free account on Invetso →